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Abstract
Background: The high prevalence of atrial fibrillation (AF) in the very elderly popula-
tion (aged >80 years) might be underestimated. The elderly are at increased risk of 
both fatal stroke and bleeding. The Optimal Thromboprophylaxis in Elderly Chinese 
Patients with Atrial Fibrillation (ChiOTEAF) registry provides contemporary manage-
ment strategies among the elderly Chinese patients in the new era of non- vitamin K 
antagonists.
Objective: To present the 1- year follow- up data from the ChiOTEAF registry, focus-
ing on the use of antithrombotic therapy, rate vs. rhythm control strategies, and de-
terminants of mortality and stroke.
Methods: The ChiOTEAF registry analyzed consecutive AF patients presenting 
in 44 centers from 20 Chinese provinces from October 2014 to December 2018. 
Endpoints of interest were mortality, thromboembolism, major bleedings, cardiovas-
cular comorbidities, and hospital re- admissions.
Results: Of the 7077 patients enrolled at baseline, 657 patients (9.3%) were lost to 
the follow- up and 435 deaths (6.8%) occurred. The overall use of anticoagulants re-
mains low, approximately 38% of the entire cohort at follow- up, with similar pro-
portions of vitamin K antagonists (VKA) and non- vitamin K antagonists (NOACs). 
Antiplatelet therapy was used in 38% of the entire cohort at follow- up, and more 
commonly among high- risk patients (41%). Among those on a NOAC at baseline, 
22.4% switched to antiplatelet therapy alone after one year.
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1  | INTRODUC TION
Atrial fibrillation (AF) incidence is increasing over the past de-
cade1; patients with AF are older and overburdened with multi-
morbidity.2,3 The prevalence of AF in the elderly (aged >80 years) 
ranges from 10% to 17%4; however, the exact numbers might be 
underestimated due to asymptomatic AF. Likewise, age is an in-
dependent risk factor for adverse outcomes in patients with AF,5 
and the elderly are at a high risk of fatal ischemic stroke and major 
bleeding.6
Recent data demonstrate the beneficial effect of oral antico-
agulants (OACs) for stroke prevention in elderly patients with AF.7- 
12 One meta- analysis showed a significant reduction in the risk of 
stroke and systemic embolism without increasing major bleeding 
events among the elderly treated with non- vitamin K antagonist 
OACs (NOACs) compared with vitamin K antagonists (VKAs).13 A 
Taiwanese cohort study of extreme elderly (aged >90) AF patients 
showed superior effectiveness and safety of NOACs compared with 
VKAs.11 Furthermore, the use of NOACs was associated with a re-
duction in adverse events, especially the risk of intracranial hemor-
rhage.11 Despite the clear benefit of OAC therapy is maintained in 
elderly patients with AF, “real- world” data showed that OACs are 
substantially underused14- 18 due to a fear of bleeding, especially 
among those with frailty or dementia.19 Of note, the NOACs showed 
better efficacy and safety among Asian patients compared with 
non- Asians.20
The introduction of the NOACs has led to a major change in 
the landscape of stroke prevention in AF, but limited contempo-
rary nationwide data are evident from China. Thus, the prospec-
tive, nationwide Optimal Thromboprophylaxis in Elderly Chinese 
Patients with Atrial Fibrillation (ChiOTEAF) registry aimed to 
explore contemporary regional management strategies, includ-
ing antithrombotic therapy among the high- risk AF population 
of the elderly Chinese patients, in the new era of the NOACs. 
In this analysis, we present the 1- year follow- up data from the 
ChiOTEAF registry, focusing on the use of antithrombotic ther-
apy, rate vs. rhythm control strategies, and determinants of mor-
tality and stroke.
2  | METHODS
The protocol of the ChiOTEAF registry has previously been pub-
lished.21 The study was approved by the Central Medical Ethics 
Committee of Chinese PLA General Hospital, Beijing, China (ap-
proval no S2014- 065- 01) and local institutional review boards.
The registry was conducted between October 2014 and 
December 2018. Briefly, the registry population comprises consecu-
tive in- and outpatients presenting with AF to cardiologists (mainly), 
neurologist, and surgeons, enrolled in 44 sites from 20 Chinese 
provinces. The main inclusions criteria were age ≥65 years (for the 
extended analysis, AF patients aged >50 years were included) and 
the qualifying AF event in the 12 months prior to enrolment (re-
corded by a 12- lead ECG or 24 hours ECG Holter).
Data were collected at the moment of enrolment and during the 
follow- up visits (including patient visit and/or chart review and/or 
telephone follow- up) by any investigator and reported into an elec-
tronic case report form. Follow- up was performed by the local inves-
tigators, initially at 6 and 12 months in the first year and annually for 
the next 2 years. Endpoints of interest were mortality, thromboem-
bolism, major bleedings, cardiovascular comorbidities, and hospital 
re- admissions. For this analysis, we focused on 1- year outcomes.
The ChiOTEAF registry has common definitions and protocol 
for the EURObservational Research Programme Atrial Fibrillation 
(EORP- AF) General Registry.22 Based on the ESC guidelines,23 throm-
boembolic risk was categorized using the CHA2DS2- VASc score.
5 
“Low- risk” patients were defined as males with a CHA2DS2- VASc 0 or 
females with a CHA2DS2- VASc 1; “moderate risk” was defined as male 
patients with a CHA2DS2- VASc score 1 or females with a CHA2DS2- 
VASc 2; and “high risk” was defined as CHA2DS2- VASc score ≥2. 
Bleeding risk was assessed based on the HAS- BLED bleeding score.23
2.1 | Statistical analyses
Univariate analysis was applied to continuous and categorical varia-
bles. Continuous variables were reported as mean+SD and/or as me-
dian and inter- quartile range (IQR). Among- group comparisons were 
Independent predictors of stroke/transient ischemic attack/peripheral embolism 
and/or mortality were age, heart failure, chronic kidney disease, prior ischemic stroke, 
dementia, and chronic obstructive pulmonary disease.
Conclusions: The ChiOTEAF registry provides contemporary data on AF manage-
ment, including stroke prevention. The poor adherence of NOACs and common use 
of antiplatelet in these high- risk elderly population calls for multiple comorbidities 
management.
K E Y W O R D S
atrial fibrillation, mortality, prognosis, registry, stroke prevention, thromboprophylaxis
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made using a non- parametric test (Kruskal– Wallis test). Categorical 
variables were reported as percentages, and the χ2 test or Fisher's 
exact test (if required) was used for among- group comparisons.
All the statistically significant variables at univariate analysis 
and variables considered of relevant clinical interests were in-
cluded in the multivariable model to distinguish the independent 
predictors of all- cause death and/or stroke/transient ischemic at-
tack (TIA)/peripheral embolism during the 1- year follow- up period. 
A Cox proportional hazard model was performed by adjusting for 
the following covariates: sex, hypertension, coronary artery dis-
ease, liver dysfunction, and prior major bleeding. All Cox regression 
analyses were reported as hazard ratio (HR) and 95% confidence 
interval [CI]. A two- sided P- value of <.05 was considered statisti-
cally significant.
3  | RESULTS
Available data on patient demography and baseline characteristics 
in relation to clinical AF subtype are summarized in Table 1, and the 
patient disposition is shown in Figure 1. Of the 7077 patients en-
rolled at baseline, 657 patients (9.3%) were lost to follow- up and 435 
deaths (6.8%) occurred (Figure 1).
The median age of AF patients (n = 5474, 39.7% female) in re-
lation to clinical subtype was 75.0 (65.0- 82.0) years, with a vast 
majority of patients at high risk of stroke (CHA2DS2- VASc score 
≥2) (Table 1). Analysis of AF subtypes showed that those patients 
with permanent AF were older, but no statistically significant dif-
ference was found in a gender ratio between groups. Differences 
in the risk of stroke and bleeding (HAS- BLED score ≥3) strata 
were evident, with more high- risk patients in the subgroups of 
permanent and long- standing persistent AF (Table 1). Patients 
were overburdened with multi- morbidity (particularly patients 
with long- standing persistent and permanent AF), including hy-
pertension (62.6%), coronary artery disease (44.8%), heart failure 
(32.1%), diabetes mellitus (25.8%), prior ischemic stroke (20.1%) 
chronic kidney disease (10.7%), chronic obstructive pulmonary 
disease (6.8%), and dementia (2.1%).
3.1 | Symptoms at follow- up
Of those patients with reported data, 1098 (20.4%) were sympto-
matic at 1- year follow- up (Table 1), most frequently among persis-
tent and long- standing persistent AF patients (25.1% and 27.6%, 
respectively). The most common symptoms at follow- up were palpi-
tations (15.9%), shortness of breath (2.4%), and fear/anxiety (1.9%).
3.2 | Antithrombotic therapy
Overall, 5350 patients had available data on antithrombotic drugs 
at baseline and 1- year follow- up, in relation to AF type. The use of 
antithrombotic therapy at a 1- year follow- up visit, concerning an-
tithrombotic therapy used at the baseline visit is shown in Figure 2. 
Of those on a vitamin K antagonist (VKA), 75.1% remained on a VKA, 
and 9.9% had switched to a NOAC during the follow- up. Among 
those on a NOAC at baseline, 2.2% had changed to a VKA and 22.4% 
to antiplatelet therapy alone. Of those on antiplatelet therapy at the 
baseline, 14.8% had switched to OAC, and 4.5% had dual therapy 
(OAC and antiplatelet).
Drug therapies prescribed at follow- up are shown in Table 2, 
summarizing drugs used before (and after) the follow- up con-
sultation. The overall use of OACs remained low among 5350 
AF patients, approximately 37.8%– 38.8% of the entire cohort at 
follow- up, with similar proportions of a VKA (18.0%– 17.8%) and 
NOACs (20.1%– 21.1%) pre and post the follow- up consultation 
visit (Table 2, Figure 3). The use of OACs was the highest among 
persistent and long- standing persistent AF patients (51.3%, 51.1%, 
respectively), with significantly lower intake in the subgroup of 
first detected and paroxysmal AF (33.4%, 34.6%, respectively). 
The NOACs were more common among long- persistent AF 
(30.5%), while they were used only in 14.7% of those with per-
sistent AF. Antiplatelet therapy was used in 37.9%– 38.1% of the 
entire cohort at follow- up and more commonly among first de-
tected AF (44.0%– 44.2%).
Table 2B shows the use of antithrombotic therapy by stroke 
risk strata (based on the CHA2DS2- VASc score). OACs were used in 
27.9%– 29.0% of low- risk patients, in 34.2%– 35.8% of moderate- risk, 
and in 39.2%– 40.1% of high- risk patients, while the NOACs were 
used in 14.9%– 16.2% of low, 18.1%– 19.5% of moderate and 20.9%– 
21.8% of high- risk patients, respectively. Antiplatelet therapy was 
used in 41.2%– 41.3% of patients at high risk of stroke.
3.3 | Rate and rhythm control strategy
For the analysis of rate and rhythm control strategies, 6022 patients 
with available data by 1- year follow- up were included. Drugs used 
for rhythm and rate control therapy at follow- up are summarized in 
Table 2C. Beta- blockers (54.5%) and digitalis (10.2%) remained the 
most common drugs used, especially in persistent and long- standing 
persistent AF; while Class Ic and III drugs were more often used in 
paroxysmal AF (5.9% and 12.7%, respectively).
Among patients managed with rate control at baseline, only 4.2% 
continued a rate control strategy, while rhythm control was consid-
ered in 43.1% (Figure S1). Of those considered for a rhythm control 
at baseline, 23.9% continued the strategy, and 16.4% were eventu-
ally considered for a rate control therapy.
Table 3 shows the interventions performed by the 1- year fol-
low- up. Any rhythm control intervention was performed in 9% of 
the overall cohort— especially among persistent and long- standing 
persistent AF patients (12.8 and 17.6%, respectively). Catheter ab-
lation was performed in 5.5% of the population, commonly among 
paroxysmal AF patients (8%); whereas pacemaker implantation was 
required in 6.9% of permanent AF patients.
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3.4 | Mortality and morbidity
After one year, 6.8% (435/6420) of the patients enrolled in the study 
died between the enrolment and the 1- year follow- up visit (Table 4). 
Causes were categorized as cardiovascular (28.5%; 124/435) and 
non- cardiovascular (56%; 244/435).
During the 1- year follow- up, there were 321 cardiac re- 
admissions reported; 146 for arrhythmias (47 for AF/atrial flutter 
recurrence), 67 for acute coronary syndrome, and 108 for heart 
failure. In this high- risk cohort, 102 thromboembolism compli-
cations (including 62 ischemic strokes, 9 TIAs, and 18 systemic 
embolisms) and 102 major bleedings (including 18 intracranial 
hemorrhages) occurred. Patients with long- standing persistent 
and permanent AF were at the highest risk of both ischemic 
stroke/TIA and bleeding.
3.5 | Multivariate analysis
A Cox proportional hazard model was compiled to establish clinical 
factors associated with the composite outcome of stroke/TIA/pe-
ripheral embolism and/or death (Table 5). For stroke/TIA/peripheral 
embolism and/or mortality, independent predictors were age (HR: 
3.75; 95% CI: 2.85- 4.94; P <.001), heart failure (HR: 1.93; 95% CI: 
1.58- 2.34; P <.001), chronic kidney disease (HR: 1.82; 95% CI: 1.48- 
2.25; P <.001), prior ischemic stroke (HR: 1.28; 95% CI: 1.05- 1.56; 
F I G U R E  1   Patient flow as part of the ChiOTEAF registry. AF, atrial fibrillation
F I G U R E  2   Antithrombotic therapy use at 1 year based on initial/baseline antithrombotic regimen. ATT, antithrombotic therapy; VKA, 
vitamin K antagonist; NOAC, non- vitamin K anatagonist; AP, antiplatelet therapy (most commonly aspirin); OAC, oral anticoagulant therapy
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P =.015), dementia (HR: 2.40; 95% CI: 1.84- 3.14; P <.001) and 
chronic obstructive pulmonary disease (HR: 1.72; 95% CI: 1.38- 2.14; 
P <.001).
4  | DISCUSSION
In this 1- year follow- up analysis of high- risk elderly patients with 
AF, our principal findings are as follows: (a) patients are frequently 
asymptomatic, but in a fifth of AF patients, symptoms are present 
(mostly palpitations, shortness of breath, and fear/anxiety); (b) the 
use of OAC remained low, less than 40% of patients, with similar 
proportions of VKA and NOACs; (c) rhythm control was infrequent, 
with any rhythm control intervention being performed in 9% of pa-
tients (and catheter ablation in only 5.5%); (d) 1- year mortality was 
high (6.8%, with the majority being non- cardiovascular deaths) and 
independent predictors of mortality were age, heart failure, chronic 
kidney disease, chronic obstructive pulmonary disease and demen-
tia; and (e) hospital re- admissions were common, especially for ar-
rhythmic causes.
The ChiOTEAF registry is the first contemporary nationwide 
prospective survey focused on management practices among 
Chinese cardiologists, with associated follow- up data, since the in-
troduction of NOACs. It was designed to have aligned definitions 
of clinical outcomes and a common protocol with the EORP- AF 
registry to compare AF management between European and 
Chinese populations.
While patients are frequently asymptomatic, symptoms at 
1- year follow- up are common among persistent and long- term 
persistent AF patients (but not paroxysmal AF), particularly palpi-
tations and shortness of breath. Of note, over 50% of patients were 
treated with beta- blockers; and rhythm control drugs were used 
in 12.6% of patients (particularly amiodarone in the paroxysmal 
AF subgroup). Consistent with symptom- based management, any 
rhythm control intervention was limited and performed only in 9% 
of the overall cohort (most commonly in persistent and long- term 
persistent AF).
Given that many elderly AF patients are asymptomatic, oppor-
tunistic screening is recommended for early AF detection in those 
aged ≥65 years.24 Likewise, the rhythm control strategy should be 
recommended for symptomatic patients to mitigate their symp-
toms and improve the quality of life.24 In the elderly, rate control 
is often the management of choice25; while rhythm control may be 
a preferable strategy among younger AF patients (aged <65 years), 
resulting in a higher rate of sinus rhythm restoration and a lower risk 
of all- cause mortality than rate control strategy.26 An increasingly 
common approach is to use catheter ablation as first- line treatment 
to reduce AF- related adverse clinical outcomes among patients 
with recently diagnosed AF, with superior results compared to anti- 
arrhythmic drugs.27- 29
The ChiOTEAF registry showed that the overall use of OACs 
was relatively low (38% of patients at follow- up), with similar up-
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In comparison, data from European registries shows over 80% of 
AF patients being anticoagulated, and NOACs account for 40% of 
OACs.22,30- 32 However, an improvement in the use of OACs among 
Chinese patients can be observed as compared to the data from 
the Clinical Epidemiology of Atrial Fibrillation in Asia and previ-
ous Chinese registries.33,34 The use of OACs is increasing steadily, 
and most recently, the Chinese Atrial Fibrillation Registry Study 
showed that 36.5% of patients with AF and CHA2DS2- VASc scores 
≥2 were anticoagulated.34 Indeed, prior papers33,34 have high-
lighted the poor uptake of OACs in China, and the reasons may be 
multifactorial. These include patient's perceptions, physician/pre-
scriber concerns about bleeding and costs (in the case of NOACs).
Despite guideline recommendations, we found that antiplatelet 
therapy (commonly aspirin) was still used in 23.7% of low- risk and 
41% of high- risk patients. When a NOAC was discontinued, over 
a fifth of patients was started on antiplatelet therapy. However, 
the reasons for this antiplatelet “overuse” in Chinese patients are 
not evidence- based; indeed, OACs were found to have superior 
efficacy with similar safety than aspirin among the elderly with 
AF.8,35 In the EORP- AF Long- Term Registry, antiplatelet ther-
apy was prescribed in 20% of patients, while 6.4% had no anti-
thrombotic treatment.32 The poor adherence of OACs at 1- year 
follow- up and common use of antiplatelet in ChiOTEAF registry 
reflected the real- world clinical practice, partly contributed by 
patient's risk profile, with complex comorbidities in these elderly 
population, thus highlighting cardiovascular risk and comorbidities 
management. Given that antiplatelet therapy is still commonly 
used in China,36 planned analyses of the ChiOTEAF registry might 
help addressing this “gap” and determine the reasons for OACs 
withholding in Chinese patients.
Given that stroke prevention is central to AF management, 
better education and awareness are needed to improve outcomes 
in this AF population.37 Indeed, guideline- driven anticoagulation 
is related to significantly better outcomes in the elderly (including 
F I G U R E  3   Antithrombotic therapy at 1 year comparing before vs. after visit/consultation. ATT, antithrombotic therapy; FU: follow up. 
VKA, vitamin K antagonist; NOAC, non- vitamin K antagonist; AP, antiplatelet therapy (most commonly aspirin); OAC, oral anticoagulant 
therapy
















(n = 182) P- value
Rhythm control 
intervention, n (%)
545 (9.05%) 12 (9.60%) 303 (8.02%) 103 (12.84%) 37 (17.62%) 81 (8.76%) 9 (4.95%) <0.001
Pharmacological 
cardioversion, n (%)
140 (2.32%) 3 (2.40%) 107 (2.83%) 16 (2.00%) 9 (4.29%) 4 (0.43%) 1 (0.55%) <0.001
Electrical 
cardioversion, n (%)
21 (0.35%) 2 (1.60%) 8 (0.21%) 7 (0.87%) 0 (0) 2 (0.22%) 2 (1.10%) 0.003
Catheter ablation, 
n (%)
332 (5.51%) 4 (3.20%) 303 (8.02%) 13 (1.62%) 1 (0.48%) 3 (0.32%) 8 (4.40%) <0.001
Pacemaker 
implantation, n (%)
329 (5.46%) 4 (3.20%) 206 (5.45%) 40 (4.99%) 14 (6.67%) 64 (6.92%) 1 (0.55%) 0.013
Implantable 
defibrillator, n (%)
26 (0.43%) 1 (0.80%) 16 (0.42%) 3 (0.37%) 1 (0.48%) 5 (0.54%) 0 (0) 0.911
AF surgery, n (%) 54 (0.90%) 1 (0.81%) 34 (0.91%) 6 (0.75%) 1 (0.48%) 2 (0.22%) 10 (5.81%) <0.001
Abbreviation: AF, atrial fibrillation.
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lower risk of all- cause and cardiovascular deaths).38 In contrast, 
both under- treatment and over- treatment increases the risk of 
death and thromboembolism among AF patients (HR: 1.679; 
95% CI: 1.202- 2.347 and HR: 1.622; 95% CI: 1.173- 2.23; respec-
tively).39 Another study showed that multimorbidity was an inde-
pendent factor of withholding OAC, while frequent falls and frailty 
were the most common reasons for non- prescription of OACs in 
the elderly.40
Furthermore, our data show high morbidity and mortality rates. 
Indeed, 1- year mortality was 6.8% in all cohort, particularly from 
non- cardiovascular causes. During the follow- up, 89 thromboem-
bolism complications occurred. Independent predictors for stroke/
TIA/peripheral embolism and/or mortality included age, heart fail-
ure, chronic kidney disease, prior ischemic stroke, dementia, and 
chronic obstructive pulmonary disease. Similarly, the European data 
of AF patients showed that overall mortality rates remained high 
(5%) during the 2- year follow- up, but mostly due to cardiovascular 
causes (61.8%).41 Accordingly in the AFFIRM trial, the diagnosis of 
heart failure, chronic obstructive pulmonary disease, and osteopo-
rosis were associated with an increased risk of all- cause mortality 
among elderly AF patients.3
Consistent with other registries, hospital re- admissions were 
common in our cohort, especially for cardiac causes (atrial ar-
rhythmias and heart failure). The increasing number of AF- related 
hospitalizations is acknowledged as a major healthcare costs.42 A 
recent RCT43 assessed the impact of integrated care supported 
by the mobile AF Application (mAFA) on clinical outcomes among 
Chinese patients with AF and ≥2 stroke risk factors during a 
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244 (56.1%) 40 (47.6%) 55 (66.3%) 31 (56.3%) 8 (50%) 52 (59.1%) 58 (53.2%)
Unknown 67 (15.4%) 8 (9.5%) 10 (12%) 9 (16.4) 5 (31.2) 11 (12.5%) 23 (21.1%)
(b) Morbidities
ACS, n (%) 67 (1%) 15 (1.6%) 9 (0.4%) 10 (1%) 4 (2.1%) 12 (1.4%) 17 (1.8%)
Heart failure, 
n (%)




102 (1.6%) 13 (1.4%) 17 (0.7%) 16 (1.6%) 5 (2.7%) 24 (2.7%) 27 (2.9%)
Ischemic stroke, 
n (%)
62 (1%) 8 (0.8%) 13 (0.5%) 5 (0.5%) 4 (2.1%) 17 (1.9%) 15 (1.6%)








18 (0.2%) 0 (0%) 3 (0.1%) 5 (0.5%) 0 (0%) 8 (1%) 2 (0.2%)
Extracranial 
bleeding, n (%)








47 (0.7%) 11 (1.2%) 13 (0.5%) 2 (0.2%) 0 (0%) 5 (0.6%) 16 (1.7%)
Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; TIA, transient ischemic attack.
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12- month follow- up. The composite endpoint of ischemic stroke/
systemic thromboembolism, death, and re- hospitalization was 
lower in the mAFA patients than usual care.43,44 Among the mAFA 
group, lower rates of OAC- related bleeding (due to the mitigation 
of modifiable bleeding risk factors) and an increase in the use of 
OAC (from 63.4% to 70.2%) was observed as compared to stan-
dard care.45 Indeed, implementing digital healthcare models into 
holistic care pathways of patients with AF may improve patients 
awareness and treatment acceptance, resulting in better out-
comes and OACs compliance.46- 48
4.1 | Limitations
The primary limitation of the study is its observational nature, and 
given its modest size, it was not powered to detect differences 
in some endpoints. Patients were enrolled in 44 centers, which 
implies a potential variability in the therapeutic strategies for AF. 
Moreover, the enrolment period was relatively long, which may af-
fect the generalizability of the results. There was a moderate pro-
portion of patients lost to follow- up (9.3%) consistent with large 
European registries.49 Also, the causes of 67 deaths (15.4%) are 
unknown, and 919 patients have unknown (182 patients)/missing 
data (737 patients) of the AF type. Finally, data on anticoagulation 
control are not currently available for this cohort and cannot be 
considered in this analysis.
5  | CONCLUSIONS
The Optimal Thromboprophylaxis in Elderly Chinese Patients with 
Atrial Fibrillation registry provides contemporary data on AF manage-
ment, including stroke prevention. The rate of OAC use was <40%, 
and antiplatelet therapy is still commonly prescribed among high- risk 
patients. Given that Chinese patients with AF are increasingly elderly 
and overburdened with multimorbidity, our large cohort data may 
help establish best practices to reduce morbidity and mortality.
5.1 | Clinical perspectives
Stroke prevention is central to AF management; better education and 
awareness are needed to improve outcomes in high- risk AF populations. 
Given the substantial clinical impact and healthcare burden associated 
TA B L E  5   Multivariate analysis
Clinical variable Hazard ratio
95% CI
P- valueLow High
(a) Stroke/TIA/peripheral embolism and/or mortality
Age >75 years 3.75 2.85 4.94 <0.001
Heart failure 1.93 1.58 2.34 <0.001
Chronic kidney disease 1.82 1.48 2.25 <0.001
Prior ischemic stroke 1.28 1.05 1.56 0.015
Dementia 2.40 1.84 3.14 <0.001
COPD 1.72 1.38 2.14 <0.001
(b) Mortality
Age >75 years 4.02 2.95 5.49 <0.001
Heart failure 2.24 1.78 2.81 <0.001
Chronic kidney disease 1.98 1.59 2.48 <0.001
Prior ischemic stroke 1.21 0.97 1.49 0.09
Dementia 2.41 1.80 3.21 <0.001
COPD 1.59 1.26 2.03 <0.001
(c) Stroke/TIA/peripheral embolism
Age >75 years 2.66 1.42 5.00 0.002
Heart failure 1.11 0.66 1.87 0.696
Chronic kidney disease 1.00 0.52 1.91 0.997
Prior ischemic stroke 1.90 1.15 3.15 0.012
Dementia 1.90 0.86 4.20 0.11
COPD 2.85 1.60 5.07 <0.001
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; TIA— transient ischemic attack. Adjusted for sex, diabetes 
mellitus, hypertension, coronary artery disease, liver dysfunction, prior major bleeding.
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with AF, the collection of prospective data from local AF cohorts may 
help establish best practice to reduce AF- related morbidity and mortality.
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